Macula Society
Fluorescein Cases for 2008

Wednesday, March 26, 2008

Fluorescein Angiography/Retinal Case Conference

4:45 - 6:55 p.m. Chair: Lawrence A. Yannuzzi
                Moderator: William Mieler

4:45 p.m. Anita Agarwal
          Mystery

4:50 p.m. J. Arevalo
          Unknown case

4:55 p.m. James Augsburger
          Optic Disc Lesion

5:00 p.m. Charles Barr
          Benign Concentric Macular Dystrophy

5:05 p.m. David Brown
          Cystoid Macular Edema Secondary to Paclitaxel

5:10 p.m. Gary Brown
          A Cost-Effective, No, Very Cost-effective Intervention

5:15 p.m. Tom Chang
          Unknown case

5:20 p.m. Michael Goldbaum
          Child with Hypopigmented Retinas

5:25 p.m. Michaella Goldstein
          Exudative Retinal Detachment

5:30 p.m. Justin Gottlieb
          Posterior Uveitis

5:35 p.m. Simon Harding
          Acute Maculopathy on a Madagascar Honeymoon

5:40 p.m. Nancy Holekamp
          Scotoma Formation after Exposure of Retinal Pigmented
          Epithelium to Indocyanine Green

5:45 p.m. Michael Klein
          Clinicopathologic Correlation of Retinal Angiomaticous
          Proliferation in Age-related Macular Degeneration

~22~
Macula Society
Fluorescein Cases for 2008

Wednesday, March 26, 2008
continued

5:50 p.m.  Noemi Lois
Mystery Case

5:55 p.m.  Andrew Lotery
An Unusual Retinal Finding Resulting from the Iraq War

6:00 p.m.  H. McDonald
Unknown

6:05 p.m.  William Mieler
Unknown case

6:10 p.m.  Jose Pulido
URO

6:15 p.m.  Jerry Shields
Unknown Tumor Case

6:20 p.m.  Jason Slakter
Mystery Case

6:25 p.m.  Richard Spaide
Unknown

6:30 p.m.  Janet Sunness
Foveal Preservation in Geographic Atrophy Associated with
AMD

6:35 p.m.  Paul Tornambe
A Dramatic Response in the Fellow Eye to Avastin in a Patient
with Severe Bilateral PDR

6:40 p.m.  Daniel Weidenthal
Disabling Illness Caused by CSF Pressure Fluctuation

6:45 p.m.  Lawrence Yannuzzi
Mystery Case

6:50 p.m.  Thomas Wolfensberger
Weight Loss Before Vision Loss

6:55 p.m.  End session
2008
Scientific Program

Thursday, Friday and Saturday

March 27 – 29, 2008
The Breakers
Palm Beach, Florida
THURSDAY, MARCH 27, 2008

SESSION I
Hereditary Retinal Disease/Miscellaneous Macular Diseases

Chair: Edwin Stone
Moderator: Francisco Rodriguez

7:30 a.m. A New Macular Dystrophy with Pigment Spots, Cysts, and Hemorrhage
            Stephen R. Russell MD

7:36 a.m. Cell-based Therapies for Retinal Degeneration
            Peter J. Francis, MD, PhD

7:45 a.m. Molecular Studies and Phenotype-Genotype Correlation in Female Carriers of a Colombian Family with X-Linked Juvenile Retinoschisis
            Francisco J. Rodriguez, MD

7:51 a.m. OCT Prevalence of CME in RP Patients Without Cystic Changes on Fundus Exam
            Gerald A. Fishman, MD

8:00 a.m. Two-color Pupillometry for Assessment of Inherited Retinal Disease
            Edwin M. Stone, MD, PhD

8:09 a.m. Unilateral Retinal Pigment Epithelium Dysgenesis
            Salmon Y. Cohen, MD, PhD

8:15 a.m. Retinal Effects of Erectile Dysfunction Drugs Taken on a Daily Basis
            Michael Marmor, MD

SESSION II
AMD Basic Science

Chair: Bert Glaser
Moderator: Ivana Kim

8:21 a.m. Vitreous Proteome in Wet Macular Degeneration vs. Non-neovascular Disease
            Bert M. Glaser, MD

8:30 a.m. Electrotaxis of Retinal Pigment Epithelial Cells: a Future Alternative in the Management of Atrophic Age-related Macular Degeneration and Other Retinal Diseases?
            Noumi Luis, MD, PhD, FSCS(Ed)

8:39 a.m. Selective Tubulin Inhibitors Show Evidence of Antiangiogenic and Angiolytic Effects in Animal Model of AMD
            Craig M. Greven, MD

~26~
8:48 a.m. Extracellular Matrix Transplants Improve RPE Survival on Aged Bruch’s Membrane
Marco A. Zarbin, MD, PhD, FACS

SESSION III
AMD Genetics and Risk Factors

Chair: Andrew Lotery
Moderator: Emily Chew

8:54 a.m. Age-related Macular Degeneration and Risk of Coronary Heart Disease and Stroke: The Cardiovascular Health Study
Tien Y. Wong, MD, PhD

9:03 a.m. Age-related Macular Degeneration is Associated with the HLA Cw*0701 Genotype and Natural Killer Cell Receptor AA Haplotype
Andrew J. Lotery, MD, FRCOphth

9:09 a.m. Genotype-phenotype Correlations for Exudative Age-related Macular Degeneration Associated with Homozygous HTRA1 and CFH Genotypes
Eric H. Sowied, MD, PhD

9:18 a.m. Correlation of Advanced Age-related Macular Degeneration Phenotypes with Variants in the LOC387715/ARMS2/HTRA1 Region
Ivana K. Kim, MD

9:27 a.m. Gene and Environment Interaction in Age-related Macular Degeneration: Towards Customized Medicine
Kang Zhang, MD, PhD

9:33 a.m. Reticular Pseudodrusen in Age-related Macular Degeneration (AMD)
Anita Agarwal, MD

9:39 a.m. Ten-Year Estimated Progression Rates to Neovascular AMD and Central Geographic Atrophy from the Age-related Eye Disease Study (ARFDS)
Emily Y. Chew, MD

SESSION IV
AMD Imaging

Chair: David Brown
Moderator: Cynthia Toth

9:45 a.m. Combined Cases of Polypoidal Choroidal Vasculopathy and Typical Age-related Macular Degeneration
Tomohiro Iida, MD
9:51 a.m. Relationship Between Angiographic and OCT Parameters for Quantifying Choroidal Neovascular Lesions
Srinivas R. Sadda, MD

9:57 a.m. Ranibizumab (LUCENTIS®) for Neovascular Age-related Macular Degeneration (AMD): Optical Coherence Tomography (OCT) vs. Visual Acuity (VA) Changes in PIER Study
David M. Brown, MD, FACS

10:06 a.m. Photoreceptor Changes over Drusen Imaged with Spectral Domain OCT
Cynthia A. Toth, MD

10:15 a.m. The Minnesota Grading System of Autofluorescence for Eyebank Eyes
Timothy W. Olsen, MD

10:21 a.m. **Break**

**SESSION V**
**AMD Visual Function/Psychosocial**

*Chair: Usha Chakravarthy*  
*Moderator: Simon Harding*

10:41 a.m. A Case Control Study of the Usefulness of Preferential Hyperacuity in Detecting Progression of Early to Late AMD
Usha Chakravarthy, MD, PhD

10:47 a.m. Multicenter Study of a New Home Perimeter for CNV Detection
Michaela Goldstein, MD

10:53 a.m. Patterns of Referral of AMD Patients for Low Vision Intervention in the Anti-VEGF Era
Janet S. Sunness, MD

10:59 a.m. The Relationship Between Visual Acuity and Health-related Quality of Life. Report from the UK VPDT Cohort Study
Simon P. Harding, FRCOphth, MD

11:05 a.m. **Presentation of the Donald M. Gass Medal**

11:10 a.m. **Rosenthal Foundation Lecture and Award Presentation**

**SESSION VI**
**Surgery**

*Chair: HR Macdonald*  
*Moderator: Judy Kim*

11:30 a.m. Treatment of Lamellar Macular Holes Associated with Epiretinal Membranes
John T. Thompson, MD
11:35 a.m. Prognostic Factors in Idiopathic Epiretinal Membrane Removal  
_Fudy E. Kim, MD_

11:41 a.m. Unexplained Visual Loss Following Routine Vitrectomy for Epiretinal Membrane  
_H. Richard McDonald, MD_

11:47 a.m. **Five-minute Discussion on Previous Papers**

11:52 a.m. Specific Cleavage of the Posterior Vitreous-ILM Interface by Dispase: Modulation of Enzyme Activity by Calcium  
_Lucian V. Del Priore, MD, PhD_

12:01 p.m. 360° Retinotomy for the Treatment of Complex Retinal Detachment  
_Neelakshi Bhagat, MD, MPH, FACS_

12:10 p.m. Maximum Visual Acuity Obtained from Repair of the Detachment Emanating from Retinoschisis  
_Harvey A. Lincoff, MD_

12:19 p.m. Endophthalmitis after 25- versus 20-Gauge Vitrectomy: A Multicenter Study  
_Harry W. Flynn, Jr. MD_

---

**SESSION VII**

**Uveitis**

*Chair: Rick Spaide*  
*Moderator: Jose Pulido*

12:25 p.m. Initial Results of QuantiFERON-TB Gold Testing in Patients with Uveitis  
_Jose S. Pulido, MD, MS, MPH, MBA_

12:31 p.m. Photoreceptor Outer Segment Abnormalities as a Cause of Blind Spot Enlargement in Acute Zonal Occult Outer Retinopathy-Complex Diseases  
_Richard F. Spaide, MD_

12:40 p.m. Restored Photoreceptor Outer Segment Damage in MEWDS  
_Sojo Kishi, MD_

12:49 p.m. Analysis of Eight Major AMD-associated Alleles in Patients with Multifocal Choroiditis: Strong Association with Complement Factor H  
_K. Bailey Freund, MD_

---
SESSION VIII
Pharmacology-Treatment of Miscellaneous Diseases

12:58 p.m. Low Fluence Photodynamic Therapy in Chronic Central Serous Chorioretinopathy: Blind Randomized Clinical Trial of Efficacy and Safety
Francesco Bascia, MD

1:07 p.m. Intravitreal Bevacizumab as a Salvage Treatment for ROP
Ruth Siegel, MD

1:16 p.m. Adjourn

FRIDAY, MARCH 28, 2008

SESSION IX
Basic Science-Miscellaneous

Chair: Joan Miller Moderator: David Zacks

7:30 a.m. Modulation of VEGF Level in RPE Cells by Inhibition of Alpha V Integrins
Dov Weinberger, MD

7:39 a.m. Endogenous Endostatin Inhibits Choroidal Neovascularization
Joan W. Miller, MD

7:48 a.m. Pre-clinical Evaluation of Six Novel Dyes for Chromovitrectomy
Michel E. Farah, MD

7:57 a.m. The X-linked Inhibitor of Apoptosis (XIAP) as a Photoreceptor Neuroprotectant During Periods of Retinal-RPE Separation
David N. Zacks, MD, PhD

8:06 a.m. Expression Studies of Laser-Induced RPE Stress
Shalesh Kaushal, MD, PhD

8:15 a.m. Clinical and Experimental Neuroglial Remodelling Following Resolution of Acute Macular Edema
Jose A. Sabel, MD

8:21 a.m. RVM Analysis of Multifocal ERGs of Eyes in HIV-Positive Subjects without Infectious Retinitis Shows Deficiencies
Michael H. Goldbaum, MD
SESSION X
Tumors

Chair: Bill Harbour                  Moderator: James Augsberger

8:27 a.m.   Ambient UVR Exposure and Risk of Death from Ocular Melanoma
            Evangelos S. Gragoudas, MD

8:36 a.m.   A Clinically and Prognostically Relevant Molecular Classification of Uveal Melanoma
            J. William Harbour, MD

8:45 a.m.   Quality of Evidence about Effectiveness of Treatments for Metastatic Uveal Melanoma
            James J. Augsburger, MD

8:54 a.m.   Targeting Regional Hypoxia Enhances Retinoblastoma Tumor Control: Use of 2-DG as a Novel Therapeutic Strategy
            Timothy G. Murray, MD, MBA, FACS

SESSION XI
Neovascular AMD Pharmacology Monotherapy Part 1

Chair: Neil Bressler                  Moderator: Carl Regillo

9:03 a.m.   Endophthalmitis Following Anti-VEGF Injections in a Retinal Practice Setting
            Michael J. Elman MD

9:08 a.m.   A Phase I Open-Label Study of Single and Repeated Doses of Intravitreal JSM6427, a Small Molecule Integrin Antagonist, in Neovascular Age-related Macular Degeneration
            Anthony P. Adamis, MD

9:13 a.m.   Primary Intravitreal Bevacizumab (Avastin) for Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration: Results of the Pan-American Collaborative Retina Study Group at 12-months Follow-up
            J. Fernando Arevalo, MD, FACS

9:18 a.m.   Intravitreal Bevacizumab in the Management of Peripapillary Subretinal Neovascular Membranes
            Mandi D. Conway, MD

9:23 a.m.   A Phase 2, Randomized, Controlled Dose-Ranging and Interval-Ranging Study of Intravitreal VEGF Trap in Patients with Neovascular Age-related Macular Degeneration
            Quan Dong Nguyen, MD, MSc
9:29 a.m. A Phase 2, Randomized, Controlled Dose- and Interval-Ranging Study of Intravitreal VEGF Trap in Patients with Neovascular Age-related Macular Degeneration: OCT and Fluorescein Angiographic Outcomes
  *Jason S. Slakter, MD*

9:35 a.m. Comparison of Lesion Characteristics between Ranibizumab (LUCENTIS®) Treated Patients who Lost or Gained Visual Acuity (VA) in the MARINA and ANCHOR Trials
  *Philip J. Rosenfeld, MD, PhD*

9:41 a.m. Nine-minute Discussion on Previous Papers

9:50 a.m. Presentation of the Arnall Patz Medal

9:55 a.m. W. Richard Green Lecture and Presentation of Award

10:15 a.m. Break

**Neovascular AMD Pharmacology Monotherapy Part 2**

**Chair: Anthony Adamis**

**Moderator: Jason Slakter**

10:35 a.m. Seemingly Paradoxical Results from ANCHOR: Relationship of Changes between Visual Acuity and Patient-reported Visual Function Following AMD Treatment
  *Neil M. Bressler, MD*

10:41 a.m. Ranibizumab (LUCENTIS®) for Neovascular Age-related Macular Degeneration (AMD): Two-year Angiographic Results of PIER Study
  *Allen C. Ho, MD*

10:47 a.m. Ranibizumab in Neovascular Age-related Macular Degeneration (AMD): Crossover/ Rollover Treatment Effects in PIER Study
  *Carl D. Regillo, MD*

10:52 a.m. Ranibizumab (LUCENTIS®) Safety in Previously Treated and Newly Diagnosed Patients with Neovascular Age-related Macular Degeneration (AMD): The SAILOR Study
  *Elias Reichel, MD*

10:58 a.m. Comparison Study of Remission Intervals in Patients Treated with Ranibizumab vs. Bevacizumab for Neovascular AMD
  *Tom S. Chang, MD*

11:03 a.m. Treatment of Non-vascularized Pigment Epithelial Detachments with Ranibizumab
  *Herbert L. Cantrill, MD*

11:09 a.m. Nine-minute Discussion on Previous Papers

~32~
SESSION XII

Neovascular AMD Pharmacology Combination Therapy

Chair: Paul Tornambe

Moderator: Michael Potter

11:19 a.m. Combination Photodynamic Therapy and Bevacizumab Reduces the Retreatment Rate in a Randomized, Controlled, Double-Masked Study of Low and Very Low Fluence Laser in Age-Related Macular Degeneration

Michael J. Potter, MD, FRCSC

11:24 a.m. Triple Therapy for the Treatment of Wet AMD

Albert J. Augustin, MD

11:30 a.m. Combination Therapy with Verteporfin PDT, anti-VEGF Agents, and Corticosteroids: Results of Two Visudyne Registry Databases

William F. Mieler, MD

11:36 a.m. Triple Therapy for Choroidal Neovascularization Due to Age-related Macular Degeneration. Ranibizumab, Intravitreal Triamcinolone Acetonide, and Verteporfin PDT. Early Vascular Changes

Paolo Lanzetta, MD

11:41 a.m. Combined Intravitreal Bevacizumab and Triamcinolone for Exudative Age-related Macular Degeneration

Jost B. Jonas, MD

11:46 a.m. Pegaptanib Sodium as Maintenance in Patients with Neovascular AMD: Interim Results of the Level Study

Thomas R. Friberg, MS, MD

11:51 a.m. A Study to Evaluate the Safety and Feasibility of Radiotherapy and Bevacizumab (Avastin©) for the Treatment of Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Jeffrey S. Heier, MD

11:57 a.m. Ten-minute Discussion of Previous Papers

SESSION XIII

Neovascular AMD Pharmacology–Miscellaneous

Chair: Gary Brown

Moderator: Michael Klein

12:07 p.m. The Comparative Effectiveness of Vitreoretinal Interventions

Gary C. Brown, MD, MBA

12:16 p.m. Anterior Chamber VEGF Levels in Health and Disease

Paul Tornambe, MD
12:25 p.m. Sham vs. No-Treatment Controls in Randomized Clinical Trials of Treatments of Neovascular Age-related Macular Degeneration
   Barbara S. Hawkins, PhD

12:34 p.m. Intravitreal Ranibizumab for the Management of Choroidal Neovascularization in Angioid Streaks
   Anita Leys, MD

12:40 p.m. Clinicopathologic Correlation of Retinal Angiomatous Proliferation in Age-related Macular Degeneration
   Michael Klein, MD

12:46 p.m. Adjourn

SATURDAY, MARCH 29, 2008

SESSION XIV
Basic Science-Drug Delivery
Chair: Lawrence Morse
Moderator: Baruch Kupperman

8:00 a.m. In Vitro Retinal Toxicity of Various Solubilized Steroids
   Baruch D. Kuppermann, MD, PhD

8:09 a.m. Ocular and Systemic Pharmacokinetics of an Intravitreal Dexamethasone Posterior Segment Drug Delivery System
   Anat Laewenstein, MD, MHA

8:18 a.m. Pharmacogenetic Microarray Analysis of Mouse Retinal Gene Expression Following Intravitreal Injection of Triaminolone and VEGF
   Lawrence S. Morse, MD, PhD

SESSION XV
Basic Science Imaging

8:24 a.m. Normal Data Ranges for Retinal Sensitivity, Retinal Thickness, and RNFL Thickness
   Felix N. Sabates, MD, FACS

8:30 a.m. Observation of Erythrocyte Dynamics in the Retinal Capillaries and Choriocapillaris Using ICG-loaded Erythrocyte Ghost Cells
   Robert W. Flower, DRHC

8:39 a.m. Ultra-wide Field Imaging in CMV Retinitis
   Matthew W. MacCumber, MD, PhD

8:45 a.m. Three-dimensional Imaging of PO2 in the Choroidal and Retinal Blood Vessels
   Norman P. Blair, MD
SESSION XVI
Non-diabetic Retinal Vascular Disease-Miscellaneous

Chair: Lee Janpot
Moderator: Barbara Blodi

8:54 a.m.  Idiopathic Perifoveal Telangiectasia: New Observations in this Distinct Clinical Retinal Vascular Abnormality
Lawrence A. Yannuzzi, MD

9:03 a.m.  Junctional Primary Retinal Telangiectasies
Leonidas Zografos, MD

9:12 a.m.  New Indications for Anti-VEGF Therapy: Retinal Arterial Macroneurysm (RAM) and Nonarteritic Ischemic Optic Neuropathy (NAION)
Naresh Mandava, MD

SESSION XVII
Retinal Venous Occlusive Disease

9:21 a.m.  Hypoxia Tolerance and Retinal Vein Occlusion
Martine Maugé-Fayssé, MD

9:27 a.m.  Clinic vs. Reading Center Evaluation of Dense Retinal Hemorrhage at Baseline in the SCORE Branch Retinal Vein Occlusion Study
Barbara A. Blodi, MD

9:36 a.m.  Intraocular Concentration of Growth Factors and Cytokines in Antiangiogenic Therapy of Retinal Vein Occlusion
Ursula Schmidt-Erfurth, MD

9:42 a.m.  Break

SESSION XVIII
Diabetic Retinopathy/Diabetic Macular Edema Part 1

Chair: Lloyd Aiello
Moderator: Victor Chong

10:02 a.m.  Optical Coherence Tomography Features Predictive of Visual Outcomes after Intravitreal Bevacizumab Injection for Diabetic Macular Edema
Oh Woong Kwon, MD, PhD

10:08 a.m.  Intravitreal Bevacizumab for the Treatment of Refractory Diabetic Macular Edema
Kevin J. Blinder, MD

10:13 a.m.  A Phase 2 Randomized Clinical Trial of Intravitreal Bevacizumab for Diabetic Macular Edema
Ingrid U. Scott, MD, MPH
10:18 a.m.  Agreement Between Clinician and Reading Center Gradings of Diabetic Retinopathy Severity Level at Baseline in a Phase 2 Study of Intravitreal Bevacizumab for Diabetic Macular Edema  
Susan B. Bressler, MD

10:23 a.m.  A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema: Study Design and Baseline Characteristics  
Michael S. Ip, MD

10:28 a.m.  Optical Coherence Tomography Measurements and Analysis Methods in Optical Coherence Tomography Studies of Diabetic Macular Edema  
Frederick L. Ferris, MD

10:34 a.m.  Retinal Hydration Assessment with Optical Coherence Tomography  
Tongalp H. 'Izzel, MD

10:40 a.m.  Ten-minute Discussion on Previous Papers

Diabetic Retinopathy/Diabetic Macular Edema Part 2

Chair: Rick Ferris  
Moderator: Michael Ip

10:50 a.m.  Effects of Dilation on Visual Acuity Obtained by Electronic-ETDRS Visual Acuity Testing (EVA) in Diabetic Patients  
Lloyd P. Aiello, MD, PhD

10:59 a.m.  Statin-mediated Inhibition of VEGF Expression  
Dennis M. Marcus, MD

11:04 a.m.  A Diabetic Retinopathy Telemedicine-Based Screening and Treatment Program in Guanajuato, Mexico  
George H. Bresnick, MD, MPA

11:09 a.m.  Clinically Significant Diabetic Macular Edema: Structural and Functional Parameters  
Edoardo Midena, MD

11:15 a.m.  Micropulse vs. Green Laser Therapy in Diabetic Macular Edema  
Victor Chong, MD

11:20 a.m.  Formation of Microintraparetinal Break Induces Serous Retinal Detachment in Diabetic Macular Edema  
Nagabisa Yoshimura, MD, PhD

11:26 a.m.  Ten-minute Discussion on Previous Papers

11:36 a.m.  Adjourn